scholarly journals Erythromycin Lactobionate

2020 ◽  
Author(s):  
Keyword(s):  
Erythromycin Lactobionate

Erythromycin lactobionate

1994 ◽  
Vol &NA; (489) ◽  
pp. 7
Author(s):  
&NA;
Keyword(s):  
Erythromycin Lactobionate

Investigation of the Enantioseparation of Basic Drugs with Erythromycin Lactobionate as a Chiral Selector in CE

2010 ◽  
Vol 72 (3-4) ◽  
pp. 289-295 ◽  
Author(s):  
Guangfu Xu ◽  
Yingxiang Du ◽  
Bin Chen ◽  
Jiaquan Chen
Keyword(s):  
Chiral Selector ◽  
Basic Drugs ◽  
Erythromycin Lactobionate

Stability of Erythromycin Lactobionate in Peritoneal Dialysate Solutions

1994 ◽  
Vol 14 (1) ◽  
pp. 79-81 ◽  
Author(s):  
Michael P. Kane ◽  
George R. Bailie ◽  
Dudley G. Moon ◽  
Irene Siu ◽  
George Eisele
Keyword(s):  
Peritoneal Dialysate ◽  
Erythromycin Lactobionate

Effects of Intravenous Erythromycin Lactobionate in Respiratory Infections

1987 ◽  
Vol 15 (4) ◽  
pp. 245-250
Author(s):  
A. Di Sciacca ◽  
F. Durante ◽  
G. Cucchiara ◽  
A. Ingrassia ◽  
G. Mira ◽  
...  
Keyword(s):  
Side Effects ◽  
Respiratory Disease ◽  
Clinical Symptoms ◽  
Respiratory Infections ◽  
High Plasma ◽  
Resistant Bacteria ◽  
Gram Positive Bacteria ◽  
Pharmacological Interactions ◽  
First Choice ◽  
Erythromycin Lactobionate

The antibiotic erythromycin lactobionate given intravenously acts almost exclusively on Gram-positive bacteria. Even at high plasma and tissue concentrations there is an almost total absence of side-effects. It could be considered, therefore, as first choice in the treatment of patients with infectious respiratory diseases. Most of the 40 patients admitted to the present study were elderly and all had either acute or chronic and becoming acute respiratory disease. Their clinical symptoms and levels of phlogosis improved on treatment with erythromycin lactobionate without any interruption of therapy due to side-effects and toxicity. The absence of unfavourable pharmacological interactions further enhances the usefulness of the drug. In view of the excellent response to monotherapy with erythromycin lactobionate and the few groups of resistant bacteria found in those cases when it was possible to check, it was not considered necessary to investigate any synergistic association with other antibiotics. It can be concluded, therefore, that therapy with erythromycin lactobionate in patients with infective respiratory disease is favourable and patients show excellent tolerability.

Interaction of Bile with Erythromycin Lactobionate in vitro*

1975 ◽  
Vol 5 (1) ◽  
pp. 25-31 ◽  
Author(s):  
A. E. Clarke ◽  
V. M. Maritz ◽  
M. A. Denborough
Keyword(s):  
Erythromycin Lactobionate

Neural control of small intestinal giant migrating contractions

1994 ◽  
Vol 266 (4) ◽  
pp. G576-G584 ◽  
Author(s):  
M. F. Otterson ◽  
S. K. Sarna
Keyword(s):  
Small Intestine ◽  
Neural Control ◽  
Loop Formation ◽  
Descending Inhibition ◽  
Enteric Nerves ◽  
Small Intestinal ◽  
Erythromycin Lactobionate ◽  
Erythromycin Stearate ◽  
Spontaneous Phase ◽  
Giant Migrating Contractions

We investigated the neural mechanisms of control of giant migrating contractions (GMCs) in five conscious dogs. After control recordings, a Thiry-Vella loop was prepared from the middle segment, and the remaining two segments were reanastomosed. GMCs were stimulated by intravenous administration of fentanyl and erythromycin lactobionate, oral administration of loperamide and erythromycin stearate, and gastric or intraluminal administration of cider vinegar in the loop. In the intact state, the agents stimulated GMCs in all three segments, and they propagated uninterruptedly from the point of their origin to the terminal ileum. The propagation velocity of GMCs increased, whereas that of migrating motor complexes (MMCs) decreased distally. After Thiry-Vella loop formation, the agents stimulated GMCs independently in the three segments, and they propagated only to the end of the segment in which they started. In the intact small intestine, the GMCs produced ascending and descending inhibition of spontaneous phase II contractions but did not interrupt the caudad propagation of the ongoing MMC. After Thiry-Vella loop formation, the ascending inhibition was unaltered, but the descending inhibition occurred only in the segment containing the GMC. We conclude that the propagation of GMCs in the small intestine is controlled by the enteric nerves. The extrinsic nerves control the ascending inhibition produced by GMCs, whereas the enteric nerves control the descending inhibition.

Sign in / Sign up

Export Citation Format

Share Document